Tallahassee, FL 3/21/12 (StreetBeat) -- Galena Biopharma (Nasdaq:GALE - News), a biotechnology company focused on developing innovative, targeted oncology treatments addressing major unmet medical needs to advance cancer care, today announced the appointment of Hope S. Rugo, M.D. to the Company's Scientific Advisory Board (SAB).
"We are pleased to have Dr. Rugo, an esteemed leader in breast cancer research, join our SAB," said Mark J. Ahn, Ph.D., President and CEO. "Dr. Rugo's renowned expertise in breast cancer research and treatment will offer Galena Biopharma deep insight into crucial areas for our continued progress. It is imperative that we build a world-class SAB with key opinion leaders to ensure our progress in developing novel approaches to advancing breast cancer care, and we look forward to Dr. Rugo's participation."
Dr. Hope S. Rugo is a Clinical Professor of Medicine in the Division of Hematology and Oncology at the University of California San Francisco Helen Diller Family Comprehensive Cancer Center, where she directs Breast Oncology and Clinical Trials Education and has an active clinical practice. Her research interests include novel therapies for advanced breast cancer, evaluation of circulating cells as novel markers of response and resistance to therapy, and complementary medicine and supportive care. Dr. Rugo is an investigator in the Bay Area Spore at UCSF breast cancer center, and the principal investigator of a number of clinical trials. She has published many peer-reviewed papers and has given presentations on a variety of cancer related topics. She is a member of the Alliance breast core committee and is the principal investigator of a Phase 3 CALGB therapeutic study for advanced breast cancer that has recently completed accrual. After graduating summa cum laude from Tufts University, Dr. Rugo received her M.D. from the University of Pennsylvania and completed both a residency in internal medicine and fellowship in hematology and oncology at UCSF. She also completed a two-year postdoctoral fellowship in immunology at Stanford University.
About Galena Biopharma
Galena Biopharma, Inc. is a Portland, Oregon-based biopharmaceutical company that develops innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care.
Please contact www.thestreetbeat.com for interest in our latest investor relations platform the “CEO Interview Series” with its host Steve Kanaval. The package includes a one-on-one interview with a seasoned industry professional; published segment to our web site with embedded audio/video file; and a compressed file that can be easily e-mailed out to your current and/or potential investors. Please e-mail email@example.com or call (662) 392-0740 for pricing and scheduling.